Molecules and markers for endosonographers: What do we need to know and measure?

Endoscopy

Volumn 38, Issue SUPPL. 1, 2006, Pages

  Al Haddad, M ^a   Wallace, Michael B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; PROTEIN P53; RIBONUCLEASE; RNA;

ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA METHYLATION; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; GASTROINTESTINAL TUMOR; GENE MUTATION; GENETIC MARKER; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PANCREAS DISEASE; PANCREAS JUICE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RELIABILITY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; CARCINOEMBRYONIC ANTIGEN; ENDOSCOPY, DIGESTIVE SYSTEM; ENDOSONOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PANCREATIC JUICE; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745900523     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946652     Document Type: Article

References (40)

1. Ilyin SE, Belkowski SM, Plato-Salaman CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 2004; 22 (8): 411-416
2. Pritzker KP, Azad A. Genomic biomarkers for cancer assessment: implementation challenges for laboratory practice. Clin Biochem 2004; 37 (7): 642-646
3. Brugge WR. Approach to cystic pancreatic lesions. Gastrointest Endosc Clin N Am 2005; 15 (3): 485-496, viii
4. Khalid A et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut 2004; 53 (12): 1860-1865
5. McCarthy DM et al. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases. Appl Immunohistochem Mol Morphol 2003; 11 (3): 238-243
6. Frossard JL et al. Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol 2003; 98 (7): 1516-1524
7. Hammel P et al. Diagnostic value of CA 72-4 and carcinoembryonic antigen determination in the fluid of pancreatic cystic lesions. Eur J Gastroenterol Hepatol 1998; 10 (4): 345-348
8. Brugge WR et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004; 126 (4): 1330-1336
9. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005; 23 (20): 4524-4531
10. Matsubayashi H et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006; 66 (2): 1208-1217
11. Wilentz RE et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998; 82 (1): 96-103
12. Yamada T et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998; 4 (6): 1527-1532
13. Ohuchida K et al. A highly sensitive and quantitative telomerase activity assay with pancreatic juice is useful for diagnosis of pancreatic carcinoma without problems due to polymerase chain reaction inhibitors: analysis of 100 samples of pancreatic juice from consecutive patients. Cancer 2004; 101 (10): 2309-2317
14. Myung SJ et al. Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutation. Gastrointest Endosc 2000; 51 (6): 708-713
15. Brunner TB et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005; 65 (18): 8433-8441
16. Caldas C et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8 (1): 27-32
17. Kalthoff H et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8 (2): 289-298
18. Tada M et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53 (11): 2472-2474
19. Mulcahy HE et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998; 4 (2): 271-275
20. Shi C et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004; 1 (2): 141-147
21. Caldas C et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54 (13): 3568-3573
22. Hollstein M et al. p53 mutations in human cancers. Science 1991; 253 (5015): 49-53
23. Sturm PD et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998; 186 (3): 247-253
24. Itoi T et al. Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 2005; 13 (2): 229-234
25. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103 (1): 41-47
26. Rosch T et al. Endosonographic diagnosis of submucosal upper gastrointestinal tract tumors. Scand J Gastroenterol 1992; 27 (1): 1-8
27. Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19 (2): 207-216
28. Kindblom LG et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152 (5): 1259-1269
29. Boyce GA et al. Evaluation of submucosal upper gastrointestinal tract lesions by endoscopic ultrasound. Gastrointest Endosc 1991; 37 (4): 449-454
30. DeMatteo RP et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (1): 51-58
31. Wiersema MJ et al. Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 1997; 112 (4): 1087-1095
32. Matsui M et al. Preliminary results of fine needle aspiration biopsy histology in upper gastrointestinal submucosal tumors. Endoscopy 1998; 30 (9): 750-755
33. Amin MB et al. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Correlation with mitotic count and clinical outcome. Am J Clin Pathol 1993; 100 (4): 428-432
34. Carrillo R et al. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28 (2): 160-165
35. Sarlomo-Rikala M et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11 (8): 728-734
36. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol 2001; 54 (2): 96-102
37. Ueyama T et al. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69 (4): 947-955
38. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999; 34 (5): 416-424
39. Newman PL, Wadden C, Fletcher CD. Gastrointestinal stromal tumours: correlation of immunophenotype with clinicopathological features. J Pathol 1991; 164: 107 (2)-117
40. Ando N et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002; 55 (1): 37-43